Eribulin plus trastuzumab in pretreated HER2-positive advanced breast cancer (ABC) patients: Results on safety and efficacy—An Italian multicenter experience.
Stefania Eufemia Lutrino(Ospedale A. Perrino), Saverio Cinieri(Ospedale A. Perrino), Claudio Zamagni(Policlinico S.Orsola-Malpighi), Claudia Corbo(Istituto Ortopedico Galeazzi), Sara Quercia(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Antonella Marino(University of Palermo), Marianna Giampaglia(Ospedale San Carlo), Chiara Caliolo(Ospedale A. Perrino), Serena Campidoglio(ASST Fatebenefratelli Sacco), Antonio Febbraro(Fatebenefratelli Hospital), Domenico Bilancia(Azienda Ospedaliera Ospedale San Carlo Borromeo), Laura Orlando, Elena Barbieri(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Caterina Fontanella(Centro di Riferimento Oncologico), Enrico Basso, Daniela Rubino(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Claudio Scavelli(Gallipoli Medical Research Foundation), Rosangela Romano, Annamaria Quaranta(Ospedale A. Perrino), Guido Giordano(University of Foggia)
Cited by 3
Related Papers
Gemcitabine Plus Vinorelbine Versus Vinorelbine Alone in Elderly Patients With Advanced Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2000|452
Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB Study
|Journal of Clinical Oncology|2012|368
First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial
|Journal of Clinical Oncology|2012|234